EGFR and glioblastoma: Sexton et al. addressed this problem by designing a small targeted fluorescent affibody peptide (about 7 kDa vs. 150 kDa for a full antibody) and demonstrated in a mouse xenograft GBM model almost two times increased fluorescence at the tumor edge compared to the full anti-EGFR antibody probe (42).